Despite more than doubling its revenue in 2007, Framingham-based GTC Biotherapeutics Inc. reported a $36.3 million net loss for the year.
The loss is an increase over the $35.3 loss the company reported for the previous year.
However, revenue for 2007 was $13.9 million compared to $6.1 million the previous year. Fourth quarter revenue was $3.1 million compared to $2.8 million in the same period the prior year.
The company reported a fourth quarter net loss of $9.8 million compared to a net loss of $7.4 million the year before.
GTC develops human proteins designed to prevent blood clots in surgery patients. The proteins are developed inside genetically modified goats.
